RxDoctor Payments Data

Matthew Bessom, MD

Internal Medicine · Knoxville, TNNPI 1821251166

Payments from drug & device makers

$10,994in general payments, 2019–2025

Across 762 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AbbVie$1K
  • GSK$990
  • Novo Nordisk$902
  • Boehringer Ingelheim$823
  • Lilly USA, LLC$725
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$10,966100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,994 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$255,545
Medicare patients
443
Services billed
7,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$196,673
EliquisApixaban117$122,726
TrulicityDulaglutide57$111,308
JardianceEmpagliflozin80$105,256
XareltoRivaroxaban63$59,123
MounjaroTirzepatide47$53,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$32,923
Synjardy XrEmpagliflozin/Metformin Hcl27$27,061
FarxigaDapagliflozin Propanediol17$26,680
JanuviaSitagliptin Phosphate12$17,843
Tresiba Flextouch U-200Insulin Degludec12$17,443
GemtesaVibegron13$15,083
MyrbetriqMirabegron12$13,217
SymbicortBudesonide/Formoterol Fumarate13$5,409
Spiriva HandihalerTiotropium Bromide11$5,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$902$196,673114 claims
Lilly USA, LLCTrulicity, Mounjaro$725$165,007104 claims
Boehringer IngelheimJardiance, Synjardy Xr$823$132,318107 claims
PfizerEliquis$1,916$122,726117 claims
Johnson & JohnsonXarelto$262$59,12363 claims
GSKTrelegy Ellipta$990$32,92325 claims
AstraZenecaFarxiga, Symbicort$477$32,08930 claims
MerckJanuvia$238$17,84312 claims
Sumitomo Pharma America, Inc.Gemtesa$39$15,08313 claims
Astellas Pharma US IncMyrbetriq$83$13,21712 claims
AbbVieSynthroid$1,212$2,45843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →